What to Expect From Pfizer's Q3 2026 Earnings Report

Pfizer Inc. (PFE), headquartered in New York, discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products. With a market cap of $167.8 billion, the company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. The pharmaceutical giant is expected to announce its fiscal third-quarter earnings for 2026 before the market opens on Tuesday, Nov. 3.

Ahead of the event, analysts expect Pfizer to report a profit of $0.72 per share on a diluted basis, down 17.2% from $0.87 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports.

For the full year, analysts expect Pfizer to report EPS of $2.95, down 8.4% from $3.22 in fiscal 2025. Meanwhile, its EPS is expected to remain unchanged year over year at $2.95 in fiscal 2027. 

PFE stock has outperformed the S&P 500 Index’s ($SPX) 16.1% gains over the past 52 weeks, with shares up 21.7% during this period. However, it underperformed the State Street Health Care Select Sector SPDR ETF’s (XLV) 24.6% returns over the same time frame.

Pfizer’s mixed performance reflects investor caution over declining COVID-19 product sales, aging blockbusters, and looming patent expirations. However, the company's core business remains resilient, bolstered by strong non-COVID portfolio execution, successful integration of acquisitions like Seagen and Biohaven, and growing demand for key brands such as Eliquis and Padcev. Looking ahead, Pfizer is prioritizing long-term growth through robust R&D pipelines in oncology and obesity, highlighted by the advancement of berobenatide, alongside aggressive cost-cutting and manufacturing efficiencies targeting $9.7 billion in net savings by 2029.

Analysts’ consensus opinion on PFE stock is moderately bullish, with a “Moderate Buy” rating overall. Out of 28 analysts covering the stock, eight advise a “Strong Buy” rating, one suggests a “Moderate Buy,” 17 give a “Hold,” and two recommend a “Strong Sell.” While PFE currently trades above its mean price target of $29.45, the Street-high price target of $36 suggests an upside potential of 21.6%.

On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.